Clinical Scorecard: Comparison of BEAM and Cyclophosphamide in Autologous Hematopoietic Stem Cell Transplantation for Relapsing-Remitting Multiple Sclerosis

At a Glance

Key Highlights

• ASCT is primarily used for RRMS due to stronger evidence compared to progressive MS.
• Two main conditioning regimens used: myeloablative BEAM/ATG and immunoablative Cy/ATG, both inducing high clinical remission rates.
• Safety has improved over time with intermediate-intensity regimens and better patient selection.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of MS according to revised McDonald criteria with relapsing-remitting disease course.
• Exclude primary or secondary progressive MS or clinically isolated syndrome at time of ASCT.
• Use clinical assessment (EDSS) and MRI for baseline and follow-up evaluations.

Management

• Mobilize stem cells with cyclophosphamide 2 g/m2 and G-CSF 5 mcg/kg subcutaneously.
• Perform stem cell harvest by peripheral blood apheresis targeting ≥2.0 × 10^6 CD34+ cells/kg.
• Administer conditioning regimen: either 7-day BEAM/ATG or 5-day Cy/ATG protocols with specified dosing schedules.
• Provide antimicrobial prophylaxis during neutropenia including ciprofloxacin, herpes virus and Pneumocystis jiroveci prophylaxis for at least 3 months.
• Monitor CMV and EBV reactivation in seropositive patients.

Monitoring & Follow-up

• Monitor severe adverse events using CTCAE v5.0 from conditioning start to 100 days post-ASCT.
• Assess clinical outcomes using NEDA status, relapse rates, MRI event-free survival, and EDSS changes at 3, 5, and 10 years.
• Follow-up visits with clinical and radiological assessments are required.

Risks

• Early high-intensity conditioning regimens had high toxicity and treatment-related mortality; intermediate regimens have improved safety.
• Expected transient hematological cytopenias, alopecia, and amenorrhea are not classified as adverse events.
• Potential risks include infections during neutropenia and viral reactivations.

Patient & Prescribing Data

Patients with relapsing-remitting MS undergoing ASCT in Sweden with validated registry data.

Both BEAM/ATG and Cy/ATG conditioning regimens achieve high remission rates; Cy/ATG use has increased recently due to favorable safety profile.

Clinical Best Practices

• Careful patient selection focusing on RRMS phenotype to optimize ASCT outcomes.
• Use intermediate-intensity conditioning regimens to balance efficacy and safety.
• Implement comprehensive antimicrobial prophylaxis and viral monitoring protocols.
• Ensure multidisciplinary follow-up with neurologists and hematologists including clinical and MRI assessments.
• Use standardized criteria (NEDA, EDSS) for long-term efficacy evaluation.

References

• AutoMS-Swe observational study
• Revised McDonald criteria for MS diagnosis
• Common Terminology Criteria for Adverse Events (CTCAE) v5.0